[1] 丰有吉,沈铿.妇产科学(供7年制及8年制临床医学生用)[M].2版.北京:人民卫生出版社,2010:113-119. [2] WHO.WHO guidelines for the management of postpartum haemorrhage and retained placenta (issued 2009). [3] Su LL, Chong YS, Samuel M. Oxytocin agonists for preventing postpartum hemorrhage [J]. Cochrane Database Syst Rev, 2007,18(3):CD005457. [4] Blum J, Winikoff B, Raghavan S, et al. Treatment of post-hemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin:a double-blind, randomized, non-inferiority trial [J]. Lancet, 2010, 375:217-223. [5] Winikoff B, Dabash R, Durocher J, et al. Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour:a double-blind, randomized, non-inferiority trial [J]. Lancet, 2010,375:210-216. [6] Widmer M, Blum J, Hofmeyr GJ, et al. Misoprostol as an adjunct to standard uterotonics for treatment of post-partum haemorrhage:a multicentre, double-blind randomized trial [J]. Lancet, 2010,75:1808-1813. [7] Hofmeyr GJ, Walraven G, Gulmezoglu AM, et al. Misoprostol to treat postpartum haemorrhage:a systematic review [J]. BJOG, 2005, 112:547-553. [8] Tang J, Kapp N, Dragoman M,et al. WHO recommendations for misoprostol use for obstetric and gynecologic indications [J]. Int J Gynaecol Obstet, 2013, 121:186-189. [9] Lamont RF, Morgan DJ, Logue M, et al. A prospective randomized trial to compare the efficacy and safty of hemabate and syntometrine for the prevention of primary postpartum haemorrhage [J]. Prostalandins Other Lipid Mediat, 2001, 66(3):203-210. [10] Price G, Kaplan J,Skowronski G. Use of recombinant factor Ⅶa to treat life-threatening non-surgical bleeding in a post-partum patient [J]. Br J Anaesth, 2004,93:298-300. |